UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. Anna B. Berry, MD EDUCATION: LICENSES, CERTIFICATION: PRINCIPAL POSITIONS HELD:

Transcription

1 UNIVERSITY OF CALIFORNIA, SAN FRANCISCO BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ University of California San Francisco Prepared: 10/06/2009 CURRICULUM VITAE Name: Position: Address: Anna B. Berry, MD Assistant Professor of Clinical Pathology Department of Pathology School of Medicine Mt. Zion Hospital 1600 Divisadero St., Room 206, Box 1785 University of California, San Francisco San Francisco, CA Voice: (415) FAX: (415) EDUCATION: University of Wyoming, Laramie WY B.S. Political Science, Chemistry Minor University of Nebraska Medical Center, M.D. Omaha NE Upstate Medical University, Syracuse NY Resident General Surgery Upstate Medical University, Syracuse NY Resident Anatomic/Clinical Pathology Medical College of Virginia, Richmond VA Resident Anatomic/Clinical Pathology Medical College of Virginia, Richmond VA Molecular Genetic Pathology National Cancer Institute, Bethesda MD Cytopathology LICENSES, CERTIFICATION: 2002 Medical licensure, Virginia (expired) 2003 Medical licensure, Maryland (expired) 2005 Medical licensure, California 2002 Board Certification, Anatomic Pathology and Clinical Pathology 2003 Board Certification, Cytopathology 2007 Board Certification, Molecular Genetic Pathology PRINCIPAL POSITIONS HELD: University of Maryland, Baltimore Assistant Professor Pathology now University of California, San Francisco Asst Prof.of Clin.Path Pathology

2 OTHER POSITIONS HELD CONCURRENTLY: University of Maryland, Baltimore Director, Cytopathology University of Maryland, Baltimore Director, Cytopathology ship University of San Francisco, California Director, Molecular Pathology 2005-now University of San Francisco, California Director, Molecular Genetic Pathology ship (accredited in 2007) HONORS AND AWARDS: National Merit Special Scholarship University of Wyoming Honors and Scholars Program 1992 Nebraska Medical Association Research Scholarship 2000 CAP Advocacy School Scholarship 2002 MCV Institutional Research Grant KEYWORDS/AREAS OF INTEREST: Cancer, cytopathology, fine needle aspiration, molecular diagnostics, DNA, RNA, PCR, RT-PCR, cytogenetics, FISH, quality assurance, quality improvement, translational research, apoptosis, public health, legal and regulatory issues. PROFESSIONAL ACTIVITIES CLINICAL Director, Molecular Pathology, University of California San Francisco ( % effort): My responsibilities as Director included choosing new assays, providing financial justification and planning for new assays, hiring, training, and supervising qualified staff members, identifying physical facility requirements and equipment requirements, facilitating the acquisition of these items, assuring that appropriate quality control and quality assurance procedures are followed, supervising the creation of procedures and policies, planning, supervising, and assisting with validation studies, interpreting test results, designing report formats, verifying reports, interacting with Clinicians, providing general guidance and advice regarding Clinical Molecular Pathology, and interacting with research faculty to facilitate the implementation of appropriate technology and data into patient care. During my tenure, we brought up 2 new FISH tests and our first 3 PCR-based tests, with several sequencing assays in process. We also moved into a new laboratory space. I provided design requirements and participated in all phases of the construction process for the new laboratory. Our laboratory also merged with the sister laboratory in the Laboratory Medicine Department and a full-time Director was identified. At this time, I am participating in bringing up novel tests that integrate FNA cytology and in supervising the MGP fellow. Attending Pathologist, University of California San Francisco (2005- now): I am on service in Cytopathology 50%. This includes performing and assisting with FNA procedures and interpreting FNA biopsy results, as well as interpreting all other types of cytology samples. I am currently training in ultrasound-guided FNA. I am responsible for supervising the Immunocyt testing program in this division, which I was instrumental in bringing on board. I am also on call for frozen sections about 3-4 days/month. Director, Cytopathology Division, University of Maryland Medical System ( ): My duties as Director included the daily sign out of all types of cytopathology cases, the performance of fine needle aspiration biopsies on demand, compiling statistics and conducting ongoing quality assurance and quality improvement programs, facilitating interaction with all outreach services and clinics, assuring compliance with credentialing and proficiency standards, appropriate billing practices, and appropriate documentation of services, providing 1

3 continuing education programs for staff, and supervising 4 cytotechnologists, 1 cytopathology preparatory technician, one part-time secretary, one cytopathology fellow, and residents when on service. During this time period, I instituted in house HPV testing and reorganized the Cytopathology Division. Presenter, Thoracic Oncology Group Tumor Board, University of Maryland Medical System ( ): My role in the Thoracic Oncology Group was to present all patients pathology findings at the weekly working conference and to track the patients on the service, providing input as needed regarding their pathology findings. Attending, Anatomic Pathology, University of Maryland Medical System ( ): I was on service in Anatomic Pathology %, primarily on the Cytopathology service. I also covered autopsies, some Surgical Pathology, and Anatomic Pathology on-call activities (roughly 1 in 7 weeks). SUMMARY OF CLINICAL ACTIVITIES (since June 2005, start date at UCSF) As the Director of Molecular Pathology at UCSF (which was a 50% time commitment), I evaluated and acquired necessary equipment including basic items such as freezers, and more complex equipment such as basic thermocyclers, a capillary electrophoresis instrument, and a real-time PCR instrument. I assured that the facility met the rigorous standards necessary to do this type of testing, and played the lead role in designing a new, state of the art laboratory space. I hired four highly qualified, licensed technologists, and provided training and supervision to these technologists. I identified a list of clinically useful assays, assisted with the construction of Return on Investment (ROI) analyses to justify the implementation of these assays, actively participated in the validation studies for our first PCR-based tests and new FISH tests, supervised the creation of procedures and policies, and assured that appropriate quality control and quality assurance procedures were being followed. I participated actively in the CAP inspection process, both in preparing for our lab inspection, and in inspecting a large regional reference lab (as part of the UCSF team). In addition, I worked with Dr. Joan Etzell (Laboratory Medicine) to develop additional ROI analyses for a complete test menu of molecular hematopathology assays, so that we will be able to hire additional staff and implement these tests, with an ultimate goal of pursuing outreach clients and completing the UCSF Hematopathology service. I also met monthly with all faculty involved with molecular testing, under the direction of Dr. Tim Hamill, (Laboratory Medicine) to enhance and coordinate these services and to address our common issues. I also supervised Dr. J.P. Grenert and one of our technologists, in providing an infrastructure to integrate a clinical translational research mission into the Molecular Pathology clinical laboratory. I participated in the merger of our lab with the Laboratory Medicine Molecular Diagnostics laboratory, which was successfully carried out. I also actively participated as a member of the search committee to identify a full-time director for the Molecular Oncology Division of the new merged lab. In August I turned over most of my administrative responsibilities to the new director and will now participate in clinical sign-out, research, and development of novel clinical tests, particularly as they relate to the FNA biopsy technique. On the Cytopathology service, I perform and interpret FNA biopsies, perform rapid and final interpretations and technical assistance for radiology procedures, and interpret Pap tests and non-gynecologic cytology specimens. I am currently training to perform ultrasound guided FNA biopsies in the walk-in clinic as well. I also supervise and troubleshoot the Immunocyt test, an ancillary test used in the diagnosis of recurrent bladder cancer, which I was responsible for validating and implementing in our lab. In addition, I am on call 3-4 days/month for the interpretation of frozen sections. I look forward to participating in the ASC Future of Cytopathology Summit, which will look at ways to reconfigure the subspecialty in today s changing pathology environment. I am specifically interested in ways to integrate molecular testing into the cytology lab. PROFESSIONAL ORGANIZATIONS Memberships 1997-now, College of American Pathologists , American Association of Cancer Researchers (Associate) 2

4 2000-now, United States & Canadian Academy of Pathology , Association for Molecular Pathology (Junior) 2001-now, American Society of Cytopathology 2002-now, Papanicolaou Society of Cytopathologists 2005-now, Association for Molecular Pathology 2009-current, California Society of Pathology 2009-current, South Bay Society for Pathologists Anna Berry Service to Professional Organizations CAP Residents Forum Executive Committee Delegate to House of Delegates CAP General Membership Committee Liaison from RF Executive Committee CAP PathPAC Board of Directors Junior Member 2002 AMP Training and Education Committee Junior Member 2002-now CAP Spokesperson Program Spokesperson 2004 PSC Governmental Affairs Task Force Member ASC Legislative and Regulatory Affairs Committee Member CAP Public Affairs Committee Member ASC Laboratory Advisory Committee Member CAP Molecular Pathology Resource Committee Member 2009 CAP Inspection Team Member 2009 AMA Relative Value Unit Committee Expert Advisor 2009 ASC Future of Cytopathology Summit Participant 2009-current Papanicolaou Society Education Committee Member 2009-current California Delegate to CAP House of Delegates Delegate SERVICE TO PROFESSIONAL PUBLICATIONS: 2005-now Ad hoc referee for Cancer (10 papers in past 5 years) INVITED PRESENTATIONS INTERNATIONAL 2005 Breast Simposium, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico NATIONAL 2002 CAP Leadership and Government Affairs Conference, Washington, D.C. (panelist) 2009 Urine Analysis for Bladder Cancer, University of Colorado, Denver REGIONAL AND OTHER INVITED PRESENTATIONS 1998 Continuing Education Presentation, Community General Hospital, Syracuse, NY 2000 Continuing Education Presentation, Medical College of Virginia, Department of Pathology 2002 Grand Rounds, Medical College of Virginia, Department of Pathology 2003 Maryland Society of Cytology/Metropolitan Washington Area Association of Cytology 2003 Grand Rounds, University of Maryland Medical System, Department of Gynecology 2006 An Evidence-Based Approach to Common Problems in Urology, UC San Francisco 2009 Issues in Urine Cytology, University of Colorado 2009 Urine Cytology and Ancillary Testing, Current Issues in Pathology (pending for May) 3

5 CME COURSES ATTENDED (5 years) 2004 American Society of Cytopathology Annual Meeting 2005 American Society of Cytopathology Annual Meeting 2005 Association for Molecular Pathology Annual Meeting 2005 Breast Simposium, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico 2006 An Evidence-Based Approach to Common Problems in Urology, UCSF 2007 Association for Molecular Pathology Annual Meeting 2008 United States and Canadian Association of Pathology Annual Meeting 2009 College of American Pathologists Annual Meeting Mechanisms of Disease Conference, UCSF UNIVERSITY AND PUBLIC SERVICE UNIVERSITY SERVICE DEPARTMENTAL SERVICE: (at UCSF, since appointment in June 2005) 2005-now Molecular Genetic Working Group (with Laboratory Medicine) 2005-now Hematopathology ship Committee 2005-now Cytopathology ship Committee 2007-now Molecular Genetic Pathology ship Committee, Chair 2008 Pathology Faculty Search Committee DEPARTMENTAL SERVICE: (at University of Maryland) Division Directors Committee Resident Training Committee Pathology Information Technology Committee Quality Assurance Committee AP Director Search Committee SUMMARY OF SERVICE ACTIVITIES My service activities at UCSF has included monthly meetings with the Molecular Genetic Working Group to enhance and coordinate molecular diagnostic services and to address common issues with the other section leaders. I also participate in committee meetings for the Hematopathology and Cytopathology fellowships, which are concerned with fellow selection and evaluation, curriculum planning and evaluation, and ACGME compliance. As the fellowship Director, I am the Chair of the committee for the recently accredited Molecular Genetic Pathology fellowship. I have also provided input for the departmental website for the Cytopathology and Molecular Pathology divisions and am working with several other Pathology faculty members to integrate clinical translational research activities into the Molecular Pathology clinical laboratory. I also served on a search committee for Molecular Oncology Medical Director in TEACHING and MENTORING 4

6 FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS: Anna Berry Academic Yr Course No. & Title Teaching Contribution Medical School, year 1, Metabolism and Nutrition block Laboratory Instructor, 1 laboratory Medical School, year 2, Integration and Consolidation block Lecturer; 2 lectures Medical School, year 1 Laboratory Instructor, 1 laboratory Medical School, year 2 Laboratory Instructor, 1 laboratory Medical School, year 1 Laboratory Instructor, 1 laboratory Medical School, year 2 Laboratory Instructor, 2 laboratories Medical School, year 1 Laboratory Instructor, 1 laboratory Medical School, year 2 Laboratory Instructor, 3 laboratories FORMAL SCHEDULED CLASSES FOR UMMS STUDENTS: Academic Yr. Course No. & Title Teaching Contribution Pathophysiology & Therapeutics, MSPR 522 Lecturer, 5 lectures POSTGRADUATE AND OTHER COURSES 2007 An Evidence-Based Approach to Common Problems in Urology, UC San Francisco 2007-current Cytopathology and Molecular Genetic Pathology lectures for AP residents (6 lectures/yr) Didactic, 1:1 teaching for MGP fellow (2 afternoon talks/yr) 2009 Urine Cytology and Ancillary Testing, Current Issues in Pathology (pending for May) POSTDOCTORAL FELLOWS, RESIDENTS, AND FACULTY DIRECTLY SUPERVISED OR MENTORED: Dates Name Faculty Role Current Position Wei Zhang, MD Pathology Resident at UMMS mentoring Completed Cytopathology ship at University of Penn Wenle Wang, MD Pathology Resident at UMMS mentoring Completed GU Pathology fellowship at Johns Hopkins Elaine Kling, MD Pathology Resident at UMMS mentoring Completed a Surgical Pathology fellowship at MD Anderson Naima Carter- Monroe, MD Pathology Resident at UMMS mentoring Completed an informatics fellowship at Johns Hopkins Hong Qi Peng, MD Cytopathology Clinical and Research Supervision, mentoring Assistant Professor at University of Maryland Kristen Jensen, MD Cytopathology Clinical Supervision Assistant Professor, Stanford Matthew Greenberg, Cytopathology Clinical Supervision Private Practice MD Ian Jaffe, MD Cytopathology Clinical Supervision Private Practice Judy Pang, MD Cytopathology Clinical Supervision Faculty at UCSF Rebecca Swain, MD Cytopathology Clinical Supervision Private Practice Annamieke Cytopathology Clinical Supervision Faculty at UCSF VanZante, MD, PhD James P. Grenert, MD, PhD Informal MGP Program Director, Mentor Faculty at UCSF 5

7 Joan Bernard, MD Cytopathology Veronia Velasco, Cytopathology MD Stepahnie McAlhany, Cytopathology MD PhD Poonam Vohra, MD Cytopathology Wendy Yang, MD Molecular Genetic Pathology Clinical Supervision Clinical Supervision Clinical Supervision Clinical Supervision Program Director Private Practice Private Practice Cytopathology Cytopathology Molecular Genetic Pathology Anna Berry INFORMAL TEACHING: 2003-now Slide review with clinicians as needed 2003-now Review of slides on site with clinicians during procedures 2003-now FNA procedure teaching to residents and fellows 2005-now Sign out with and Resident (cytology and molecular) 2005-now Sign out with molecular technologists 2005-now Training and mentoring molecular technologists Sign out with Resident and daily Slide review with Cytotechnologists as needed Review of Hematology slides with attending as needed for correlation SUMMARY OF TEACHING HOURS: : 495 total hours of teaching (including preparation). 15 Mentoring hours : 580 total hours of teaching (including preparation). 100 Mentoring hours : 580 total hours of teaching (including preparation). 100 Mentoring hours : 580 total hours of teaching (including preparation). 100 Mentoring hours : 580 total hours of teaching (including preparation). 100 Mentoring hours 6

8 TEACHING NARRATIVE My teaching currently is focused on resident and fellow lectures and clinical training for Cytopathology and Molecular Genetic Pathology fellows. I give 3 Cytopathology lectures and 3 Molecular Genetic Pathology lectures per year, and one slide seminar in Cytopathology as well. In addition, I provide 2 afternoon-long didactic sessions during my section rotation for the MGP fellow, as well as coordinating the didactic teaching for the MGP fellow. I also am responsible for arranging all rotations for the MGP fellow, and fulfilling all other fellowship director responsibilities (15% effort). Additionally, I supervise Cytopathology fellows and residents in the FNA clinic and for slide sign-out, about one day per week, and supervise residents and fellows in the molecular laboratory 2 days per week. I also provide informal teaching for the molecular staff as needed and for the clinical staff as needed, both in relation to molecular cases, and during on-site evaluation of FNA samples for Radiologists and other clinicians. In addition, I provide formal and informal teaching and supervision for a molecular technologist as part of our formal training program. I assist with the medical student laboratories as needed (6 labs this academic year). I will be teaching a course at the UCSF GME Course Current Issues in Pathology and have applied to teach a course at the USCAP meeting in RESEARCH AND CREATIVE ACTIVITIES PEER REVIEWED PUBLICATIONS: 1. Peng HQ, Greenwald BD, Tavora FR, Kling E, Darwin P, Rodgers WH, Berry A. Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas, Diagn Cytopathol May; 36(5): Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy, BJU Int Feb 10. [Epub ahead of print] NON-PEER REVIEWED PUBLICATIONS: Review Articles 1. Greene KL, Berry A, Konety BR. Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer, Rev Urol Fall;8(4): Books and Chapters 1. O Grady, A.B., Atkins, K.A., and Powers, C.N.: Fine Needle Aspiration Biopsy of Endocrine Glands, In: Lloyd, R.V. (Ed). Endocrine Pathology: Differential Diagnosis and Treatment. City: Humana Press, October RESEARCH PROGRAM I am interested primarily in translational research. In general, I am interested in investigating and promoting the use of molecular testing to diagnose and describe solid tumor specimens in the clinical laboratory, to provide information that is relevant to patient care. To that aim I will continue to participate in the expansion of the Molecular Diagnostics laboratory. Specifically, I will continue to validate and add tests based primarily on data that currently exists in the medical literature, with the aim of applying these tests to small tissue specimens such as 7

9 fine needle aspiration material, to improve the efficiency, detail, and accuracy of cancer diagnosis using these specimen types, limiting the time to diagnosis and improving patient care. To this aim, I have worked with several other Pathology faculty members to integrate Departmental molecular research projects into our clinical laboratory structure. During my tenure as laboratory director, we employed one technologist who was dedicated primarily to translational research, and one faculty member, who I supervise, to assist her in carrying out faculty projects. This program continues and will facilitate my future work. I am currently planning to participate in at least one project with Dr. Adil Daud in Clinical Oncology. Dr. Daud published a paper in the Journal of Clinical Oncology showing a good response to IL-12 plasmid electroporation therapy in melanoma patients. We are planning to integrate FNA biopsy testing as the best method for clinical follow-up in these patients during the Phase II trial and have submitted a proposal for an R-01 grant for this purpose. We are also working on a separate proposal integrating FNA techniques into the delivery of therapy, as well as into the monitoring phase. I have a clinical background in melanoma testing, as I completed my cytology fellowship training at the National Cancer Institute, which has a large clinical research program in melanoma. I would like to combine these experiences to move forward and collaborate with Dr. Daud more extensively on future melanoma-related research projects. In addition, I am participating in some ongoing projects related to Immunocyt and Urovysion testing, both of which were validated and instituted under my direction in January of I have been collaborating in a study evaluating the cost-effectiveness of reflex Immunocyt testing with Dr. Badrinath Konety, which arose from an abstract we presented at the AUA meeting this year. We are examining our data from 2007 and using epidemiologic analysis methods to estimate the cost savings associated with performing the Immunocyt test on all cytologically atypical urine samples. Immunocyt is not widely available at this time, and there are no published guidelines for the use of this test, so this information should be timely and clinically valuable. I am also separately analyzing our diagnostic data in relation to the reflex Immunocyt testing, looking for ways to improve our morphologic analysis, and again attempting to determine the best utilization practices for this test. I expect both of these publications to be complete before the end of the academic year. I have also been collaborating with Dr. Konety in an ongoing project to assess the value of Urovysion testing in urine specimens obtained from bladder reconstructions. These samples have characteristics that make them suboptimal for this type of analysis, and many are insufficient. While we continue to accept them for analysis, it seems likely that this is not an efficient use of resources. We are attempting to determine the best use of this test in this circumstance. I am also collaborating with Dr. Peter Carroll regarding this issue to evaluate the efficacy of using a special catheter to evaluate only the urethra for recurrence, providing a more appropriate sample for analysis. This project also arose from an abstract we presented at the AUA meeting. I am separately looking at issues related to Urovysion utilization, including frequency of testing for bladder cancer follow-up. Urovysion is a useful but very expensive test that is widely available. Clear guidelines for the use of this test would reduce health care costs and improve patient care. I am also in the process of creating innovative and targeted evaluation techniques for the MGP fellowship, which will be more specifically applicable to the practice of Molecular Genetic Pathology. I hope to publish the results of this effort at some point in the future. Finally, I am writing two chapters for a Spanish-language comprehensive book on breast cancer, one on breast cancer pathology and one on molecular techniques in breast cancer. This endeavor arose from a meeting that I spoke at in 2005 at the Universidad Autonoma de Nuevo Leon in Monterrey, Mexico at the invitation of Servando Cardona, a breast surgeon at that institution who is attempting to change the way breast cancer is treated in Mexico. He has created one of the first comprehensive breast care centers in his country and is pushing to bring current technology and practices to the forefront there. 8